In this paper, we highlight the possibility of repositioning anti-diabetic drugs as a strategy for dementia therapy by analyzing clinical trials as well as integrating the molecular perspectives from various types of dementia through the insulin/IGF-1 signaling pathway. This evidence concerns the gene INS and dementia.